How mesenchymal stem cells (MSCs) may revolutionize scar treatment. MSC therapy for keloids, hypertrophic scars, burn scars, and wound healing.
Scar formation and keloid growth are driven by dysregulated fibroblast activity: myofibroblasts overproducing type I collagen and cross-linking enzymes, excessive TGF-β1 signalling, and impaired scar remodelling. MSC therapy directly suppresses these mechanisms: MSCs reduce TGF-β1 signalling, promote MMP-mediated collagen breakdown, shift fibroblast phenotype from pro-fibrotic to normal wound-healing, and secrete anti-fibrotic hepatocyte growth factor. In burns, MSC therapy additionally promotes keratinocyte migration and epidermal regeneration, reducing the depth and extent of scar formation.
MSC therapy has evidence for: hypertrophic burn scars (50–65% volume reduction at 6 months in published series), keloid treatment (60–70% reduction in keloid index, reduced recurrence vs intralesional corticosteroid alone), post-surgical scar improvement, and atrophic acne scarring (30–50% improvement in depth/volume). Treatment is most effective for active or immature scars (under 2 years old); mature, stable scars show partial rather than complete response. Combination with laser resurfacing or microneedling is synergistic and often recommended.
Scar treatment involves direct intra-lesional MSC or MSC-conditioned media injection into the scar tissue combined with topical exosome application and IV systemic delivery. Sessions are spread across 3–5 days in Istanbul. Pre-treatment photography, 3D scar mapping, and histological assessment (if available) establish baseline. Post-treatment imaging at 3 and 6 months measures objective scar volume reduction and textural improvement.
Related articles: Mesenchymal Stem Cells (MSCs): What Every Patient Should Know | Exosome Therapy Benefits (2026 Research Update) | Understanding Stem Cell Therapy (2026 Complete Guide)
Related treatments: Anti-Aging Stem Cell Therapy | Cellular Rejuvenation Therapy | Chronic Pain Stem Cell Therapy
